BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26491904)

  • 1. Expression of Sex Determining Region Y-Box 2 and Pancreatic and Duodenal Homeobox 1 in Pancreatic Neuroendocrine Tumors.
    Akiyama T; Shida T; Yoshitomi H; Takano S; Kagawa S; Shimizu H; Ohtsuka M; Kato A; Furukawa K; Miyazaki M
    Pancreas; 2016 Apr; 45(4):522-7. PubMed ID: 26491904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2.
    Hermann G; Konukiewitz B; Schmitt A; Perren A; Klöppel G
    Virchows Arch; 2011 Aug; 459(2):147-54. PubMed ID: 21739268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.
    Yoxtheimer LM; Heymann JJ; Cohen C; Rao RA; Goyal A; Siddiqui MT
    Diagn Cytopathol; 2018 Dec; 46(12):1010-1014. PubMed ID: 30284410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of ARX expression, a novel biomarker for metastatic risk in pancreatic neuroendocrine tumors, in endoscopic ultrasound fine-needle aspiration.
    Hackeng WM; Morsink FHM; Moons LMG; Heaphy CM; Offerhaus GJA; Dreijerink KMA; Brosens LAA
    Diagn Cytopathol; 2020 Apr; 48(4):308-315. PubMed ID: 31846235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms.
    Chan ES; Alexander J; Swanson PE; Jain D; Yeh MM
    Am J Surg Pathol; 2012 May; 36(5):737-43. PubMed ID: 22498824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of PAX6 and PAX8 as immunohistochemical markers for pancreatic neuroendocrine tumors.
    Lai JP; Mertens RB; Mirocha J; Koo J; Venturina M; Chung F; Mendez AB; Kahn M; Dhall D
    Endocr Pathol; 2015 Mar; 26(1):54-62. PubMed ID: 25433656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity.
    Garbrecht N; Anlauf M; Schmitt A; Henopp T; Sipos B; Raffel A; Eisenberger CF; Knoefel WT; Pavel M; Fottner C; Musholt TJ; Rinke A; Arnold R; Berndt U; Plöckinger U; Wiedenmann B; Moch H; Heitz PU; Komminoth P; Perren A; Klöppel G
    Endocr Relat Cancer; 2008 Mar; 15(1):229-41. PubMed ID: 18310290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
    Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
    Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
    Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
    Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors.
    Arnason T; Sapp HL; Barnes PJ; Drewniak M; Abdolell M; Rayson D
    Neuroendocrinology; 2011; 93(4):249-58. PubMed ID: 21487213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.
    Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B
    Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sonic hedgehog and pancreatic-duodenal homeobox 1 expression distinguish between duodenal and pancreatic gastrinomas.
    Fendrich V; Ramerth R; Waldmann J; Maschuw K; Langer P; Bartsch DK; Slater EP; Ramaswamy A; Rothmund M
    Endocr Relat Cancer; 2009 Jun; 16(2):613-22. PubMed ID: 19240184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens.
    Haynes CM; Sangoi AR; Pai RK
    Cancer Cytopathol; 2011 Jun; 119(3):193-201. PubMed ID: 21328566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors.
    Chen MH; Yeh YC; Shyr YM; Jan YH; Chao Y; Li CP; Wang SE; Tzeng CH; Chang PM; Liu CY; Chen MH; Hsiao M; Huang CY
    J Gastroenterol; 2013 Jan; 48(1):101-8. PubMed ID: 22706573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of functional and nonfunctional neuroendocrine tumors in the pancreas and peripancreatic region.
    Wang SE; Su CH; Kuo YJ; Shyr YM; Li AF; Chen TH; Wu CW; Lee CH
    Pancreas; 2011 Mar; 40(2):253-9. PubMed ID: 20966805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
    Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
    Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial-mesenchymal transition markers in the differential diagnosis of gastroenteropancreatic neuroendocrine tumors.
    Galván JA; Astudillo A; Vallina A; Fonseca PJ; Gómez-Izquierdo L; García-Carbonero R; González MV
    Am J Clin Pathol; 2013 Jul; 140(1):61-72. PubMed ID: 23765535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.